RxDoctor Payments Data

Andrea Banty

Family · West Hollywood, CANPI 1013467745

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $36,594 of the $56,107 with a category attached, or 65.2%. Johnson & Johnson accounts for 93.6% of it on its own, with 4 other manufacturers making up the rest. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$56,107in general payments, 2019–2025

Across 104 payments — averaging $539.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$53K
  • Genentech USA, Inc.$3K
  • AbbVie$666
  • Merck$238
  • Takeda Pharmaceuticals U.S.A., Inc.$25

What the payments were for

  • Consulting fees$6,29811%
  • Speaking & faculty fees$36,59465%
  • Travel & lodging$10,19018%
  • Food & beverage$3,0255%

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,107 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$13,742
Medicare patients
109
Services billed
179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab203$5,682,594
Skyrizi On-BodyRisankizumab-Rzaa61$1,253,898
Humira(Cf) PenAdalimumab81$1,109,237
RinvoqUpadacitinib48$334,437
Humira(Cf)Adalimumab13$88,444
Mesalamine88$52,304
LialdaMesalamine24$26,342
LinzessLinaclotide18$14,640
Mesalamine ErMesalamine18$9,461
RasuvoMethotrexate/Pf11$6,042
Balsalazide Disodium17$4,062
Mercaptopurine26$2,223
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine51$1,925
CholestyramineCholestyramine (With Sugar)13$1,721
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates24$1,472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$52,537$5,682,594203 claims
AbbVieRinvoq, Humira(Cf), Linzess$666$437,52279 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in West Hollywood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →